CD38 and autoimmune thrombocytopenic purpura: Except for hematological tumors, CD38-targeting therapy, as one of the major discussed immune cell-depleting based strategies, has also been investigated and practiced in clinical trials of a wide range of diseases including SLE (24, 37), ITP (38) and IgA nephropathy (IgAN) (39, 40).